ROBIN DIBIASE: Open Payments
NPI 1255915716 · SAN LUIS OBISPO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,611 in 76 payments from 30 companies in 2025. Trend: 2023 $1,386 · 2024 $1,244 · 2025 $1,611
Food & beverage: $1,531Education: $80
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $204 |
| Exelixis Inc. | 9 | $191 |
| Novartis Pharmaceuticals Corporation | 11 | $177 |
| GlaxoSmithKline, LLC. | 4 | $104 |
| Daiichi Sankyo Inc. | 5 | $97 |
| AstraZeneca Pharmaceuticals LP | 4 | $77 |
| E.R. Squibb & Sons, L.L.C. | 3 | $54 |
| Syndax Pharmaceuticals, Inc. | 2 | $52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $51 |
| Merck Sharp & Dohme LLC | 2 | $49 |
Products named: CABOMETYX, DARZALEX, KISQALI, OJJAARA, Enhertu, KEYTRUDA, SCEMBLIX, OPDIVO.
Industry payments across CA — which companies pay providers there.
